<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report 30 'low-risk' patients with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (defined as &lt; 10% bone marrow blasts) who were treated with antithymocyte globulin (ATG) </plain></SENT>
<SENT sid="1" pm="."><plain>In total, 20 patients were evaluable at the study end-point (response to treatment at 6 months) </plain></SENT>
<SENT sid="2" pm="."><plain>The diagnosis in these 20 patients was refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) in 13, RA with excess blasts in four, and RA with ringed sideroblasts in three </plain></SENT>
<SENT sid="3" pm="."><plain>Median age was 54.5 years (range, 31-73 years) </plain></SENT>
<SENT sid="4" pm="."><plain>There were two cases of <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The bone marrow was hypocellular in eight cases and cytogenetics were abnormal in four cases </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients received lymphoglobuline (horse ATG; Sangstat, France) at a dose of 1.5 vials/10 kg/day for 5 d </plain></SENT>
<SENT sid="7" pm="."><plain>The treatment was well tolerated </plain></SENT>
<SENT sid="8" pm="."><plain>Three patients in the study died (disease progression, invasive <z:e sem="disease" ids="C0004030" disease_type="Disease or Syndrome" abbrv="">aspergillosis</z:e> and <z:mp ids='MP_0008714'>lung carcinoma</z:mp> respectively); 10 out of 20 evaluable patients (50%) responded to treatment and became transfusion independent; eight out of 13 (62%) patients with RA responded </plain></SENT>
<SENT sid="9" pm="."><plain>The median duration of response was 15.5 months (2-42+ months) at the time of analysis </plain></SENT>
</text></document>